Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research

Support

Ways to Pay

Shop by goal

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Shop by compound

CJC-1295 (without DAC)

Shop by region

Research use only - all claims made on this site are for testing and research use only. Purchasers must be 21 years of age or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

GLP1-RC-TZ

Compare pack sizes

Tap a pack to select it in the purchase panel above

Buy the 10-pack - save 67%/mg

Buy the 10-pack - save 66%/mg

Buy the 10-pack - save 67%/mg

Buy the 10-pack - save 66%/mg

Buy the 10-pack - save 65%/mg

Buy the 10-pack - save 60%/mg

Buy the 10-pack - save 57%/mg

Buy the 10-pack - save 60%/mg

Buy the 10-pack - save 66%/mg

Buy the 10-pack - save 67%/mg

Single vials ship as an add-on to a 10-vial pack - browse 10-vial packs

Lab-direct quality — full packs or single-vial samples

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same lab, same batch, same verified purity — scaled to whatever your research needs.

GLP1-RC-TZ Batch Verification

Each released GLP1-RC-TZ batch is independently analysed for chemical purity and identity, with the applicable laboratory report linked to the product batch.

New-U GLP1-RC-TZ batch evidence

Catalogue identifier: GLP1-RC-TZ

Batch number, vial count and declared mass per vial

RP-HPLC purity result for the released batch

Mass-spectrometry identity result for the released batch

Independent testing laboratory, report number and test date

Batch-linked Certificate of Analysis at /coa/tirzepatide

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Published Research Areas

Published studies examine receptor activity, pharmacokinetics and protocol-defined metabolic, glycaemic and insulin-sensitivity endpoints. The summaries below report what investigators measured in those external studies and are not use instructions for the research material supplied here.

Receptor Pharmacology

Full GIPR potency alongside cAMP-biased GLP-1R signalling, characterised in published in-vitro studies.

Metabolic Endpoints

Protocol-defined change from baseline in body mass, measured across the SURMOUNT programme.

Glycaemic Endpoints

HbA1c as a protocol-defined endpoint, measured across the SURPASS diabetes programme.

Insulin-Sensitivity Endpoints

Insulin-sensitivity markers and adiponectin, measured alongside direct GIPR-mediated adipose signalling.

Pharmacokinetics

Systemic exposure, bioavailability and apparent half-life, from published pharmacokinetic characterisation.

Overview

In short: GLP1-RC-TZ is a GIPR / GLP-1R dual-agonist research compound, commonly referred to as “Tirz” in research communities.

Key research facts

Receptor pharmacology: dual GIPR / GLP-1R agonist activity characterised in published in-vitro studies

Imbalanced agonism reported — full GIPR potency with GLP-1R signalling biased toward cAMP over β-arrestin recruitment

Aib2 and Aib13 substitutions investigated for DPP-IV and protease resistance

C20 fatty-diacid modification reported to give 99% albumin binding; apparent elimination half-life reported at ~5 days

SURMOUNT-1 RCT (NEJM 2022, PMID 35658024), 15 mg arm: investigators reported −20.9% mean change from baseline in body weight at week 72

These points summarise lab themes, not human outcomes.

Published work characterises the receptor pharmacology, structural modifications and pharmacokinetic profile of this compound class, alongside protocol-defined endpoints investigated across registered clinical programmes.

New-U batch verification and external literature are separate evidence sets: batch testing establishes analytical identity and purity for the tested material; published studies describe their own investigational materials and protocols.

Read the full scientific overview

Molecular Architecture

LY3298176 is a 39-amino-acid synthetic peptide characterised in receptor-pharmacology studies as an agonist at two incretin receptors, GLP-1R and GIPR, rather than GLP-1R alone.

Receptor Pharmacology

The literature describes the profile as imbalanced: full GIPR potency layered onto a cAMP-biased GLP-1R signal. Full pathway table: Receptor Pharmacology below.

Structural Modifications

Published structural work describes Aib2 and Aib13 substitutions investigated for protease resistance and a C20 fatty diacid attached at Lys20 via a γGlu/AEEA spacer, investigated as an albumin-binding contributor to prolonged systemic exposure.

Published Pharmacokinetics

Apparent elimination half-life is reported at approximately five days with roughly 80% subcutaneous bioavailability. Full profile: Pharmacokinetics below.

Clinical Research

Published findings summarised on this page relate to external clinical studies of the reference medicine and their respective materials and protocols. They do not establish the safety, efficacy or clinical equivalence of New-U GLP1-RC-TZ material.

Primary References

Peer-reviewed publications and registered trial records are listed in full, with DOI/PMID/NCT identifiers, in Source References below.

Receptor Pharmacology

Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Pathway Effect Why it matters GIPR Full agonist activity characterised experimentally, comparable to native GIP The arm that distinguishes the dual agonist from single GLP-1R compounds in the literature GLP-1R Agonist activity characterised as biased, favouring cAMP signalling over β-arrestin recruitment Investigated in relation to receptor desensitisation over prolonged exposure Adipose GIPR signalling Direct GIPR-mediated adipose effects characterised experimentally Investigated as a contributor to measured insulin-sensitivity markers and adiponectin Albumin-binding modification C20 eicosanedioic acid via a γGlu/AEEA spacer; 99% plasma protein binding reported Investigated as a contributor to prolonged systemic exposure (~5-day apparent half-life) Proteolytic stability Aib2 and Aib13 substitutions Structural modifications investigated for altered peptide stability against DPP-IV and proteases

Deeper dive for scientific readers

The imbalanced-agonism profile is characterised in JCI Insight (2020): full GIPR potency layered onto a cAMP-biased GLP-1R signal. In SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024) investigators reported a mean change from baseline in body weight of −20.9% at week 72 in the 15 mg arm. SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) was designed as a head-to-head comparison against semaglutide and reported −20.2% vs −13.7% at week 72. SURPASS-CVOT (NEJM 2025) compared cardiovascular outcomes against dulaglutide and reported an approximately 8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality. Insulin-sensitivity improvements beyond what change in body weight alone accounts for are discussed in the literature as consistent with direct GIPR-mediated adipose effects. Every figure here is an observation recorded in the cited external study of the reference medicine.

Common Questions People Are Asking

What is Tirzepatide in scientific research?

Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide characterised in receptor-pharmacology studies as a dual GIP / GLP-1 receptor agonist with imbalanced agonism. It is approved as a medicine in some jurisdictions under other manufacturers' brand names; the material supplied here is not that finished pharmaceutical.

What is GLP1-RC-TZ?

GLP1-RC-TZ is New-U's catalogue identifier for the laboratory research material offered through this research profile. It is not a medicine, a treatment, a generic pharmaceutical or a therapeutic product, it is not equivalent to any clinical or commercial product, and it is not offered for human or veterinary use.

Which receptor systems are examined in Tirzepatide research?

Published in-vitro pharmacology characterises two receptors: GIPR, where agonist potency is reported as comparable to native GIP, and GLP-1R, where signalling is reported as biased toward cAMP generation over β-arrestin recruitment. Structural work additionally investigates the C20 fatty-diacid albumin-binding modification and the Aib2/Aib13 substitutions for altered proteolytic stability.

What analytical testing accompanies GLP1-RC-TZ?

Each released GLP1-RC-TZ batch is tested by an independent analytical laboratory for purity by RP-HPLC area normalisation and for identity by mass spectrometry, and the result is published as a batch-linked Certificate of Analysis recording the laboratory, report number, measured purity and test date. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Where can I view the current batch COA for GLP1-RC-TZ?

The current batch certificate — laboratory, report number, measured purity and test date — is published at /coa/tirzepatide, together with the testing history for the compound.

What does >99% HPLC purity mean?

It is a purity figure obtained by reversed-phase high-performance liquid chromatography using area normalisation: the target peak accounts for more than 99% of the total integrated peak area in the chromatogram for the tested sample. It is a statement about chemical purity of that sample only, and says nothing about sterility, endotoxin content, pharmaceutical equivalence or any clinical property.

What clinical trials are referenced on this page?

Three external studies of the reference medicine: SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024), SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) and SURPASS-CVOT (NEJM 2025; DOI 10.1056/NEJMoa2505928), alongside the receptor-pharmacology characterisation in JCI Insight (2020). Each reported result on this page is attributed to its study, arm and timepoint.

How is published clinical research distinguished from New-U batch testing?

They are separate bodies of evidence. Published clinical research is external work on the approved finished pharmaceutical, conducted under those studies' own protocols; it establishes nothing about the material supplied here. New-U batch testing is analytical work on the GLP1-RC-TZ lot itself — RP-HPLC purity and mass-spectrometry identity — and it establishes nothing clinical. A certificate of analysis combined with an external clinical paper does not amount to clinical validation of GLP1-RC-TZ.

Is GLP1-RC-TZ the same as an approved branded medicine?

No. Approved branded tirzepatide products are prescription, sterile finished pharmaceuticals manufactured under cGMP by their marketing authorisation holder. GLP1-RC-TZ is unapproved laboratory research material supplied as a lyophilised powder. It is not equivalent to, a generic of, or a substitute for any approved product.

Why is Tirzepatide described as imbalanced in the literature?

Because the two receptor arms are not matched: published pharmacology reports full agonist potency at GIPR comparable to native GIP, but biased signalling at GLP-1R that favours cAMP generation over β-arrestin recruitment. The literature investigates that asymmetry in relation to receptor desensitisation over prolonged exposure.

How does Tirzepatide research differ from Retatrutide and Semaglutide research?

By receptor coverage as characterised in the literature: semaglutide research describes GLP-1R agonism, tirzepatide research describes GIPR/GLP-1R agonism, and retatrutide research investigates GLP-1R/GIPR/GCGR agonism. Only SURMOUNT-5 was designed as a head-to-head comparison (tirzepatide vs semaglutide); results drawn from separate programmes are not head-to-head comparisons.

What form is GLP1-RC-TZ supplied in?

GLP1-RC-TZ is supplied as a lyophilised powder in sealed vials, in sealed 10-vial research packs across the listed strengths, with a batch-linked Certificate of Analysis.

How should laboratory research material be stored?

Store the lyophilised powder in a freezer at −20 °C. If a laboratory protocol requires the material in solution, hold the resulting solution refrigerated at 1–6 °C, protected from light, and avoid repeated freeze–thaw cycles, which can degrade the fatty-acid modification. Storage conditions are laboratory handling information only.

Is it legal to buy Tirzepatide?

In the United States, Tirzepatide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 5 days (mean 116.7 h); steady-state exposure reported after ~4 weeks Absorption route Study protocols used subcutaneous administration; reported Tmax 8–72 h Bioavailability ~80% subcutaneous reported Metabolism / clearance Proteolytic backbone cleavage, β-oxidation of the C20 fatty-diacid chain and amide hydrolysis reported; metabolites eliminated ~66% renally / ~33% faecally; no CYP-mediated interactions Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes Reported volume of distribution ~10.3 L; 99% albumin-bound. These are pharmacokinetic observations from external studies of the reference medicine, not a handling or administration instruction for research material.

Research-Observed Effects

SURMOUNT-1 RCT (Jastreboff et al., NEJM 2022; PMID 35658024), obesity/overweight population, 15 mg arm: investigators reported a mean change from baseline in body weight of −20.9% at week 72

SURMOUNT-5 head-to-head RCT (Aronne et al., NEJM 2025; PMID 40353578): investigators reported −20.2% in the tirzepatide arm vs −13.7% in the semaglutide arm at week 72

SURPASS-CVOT RCT (NEJM 2025), 13,000+ participants vs dulaglutide: investigators reported an ~8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality

SURPASS diabetes programme: investigators reported HbA1c reductions of up to 2.58% as a protocol-defined endpoint

Insulin-sensitivity markers and adiponectin recorded as measured endpoints, discussed in the literature in relation to direct GIPR-mediated adipose signalling

Pharmacodynamic studies recorded delayed gastric emptying and reduced postprandial glucose excursions as measured endpoints

Published Research Context

Registered clinical research of the reference medicine used protocol-defined intervention arms. The SURPASS and SURMOUNT programmes included 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg arms, with a protocol-defined step-up period of roughly 20 weeks before the maintenance arm level was reached. Study protocols used once-weekly subcutaneous administration.

These figures are characteristics of external clinical trials of an approved medicine. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the reference medicine. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Decreased appetite and dyspepsia recorded as reported adverse events

Rare

Gallbladder events (cholelithiasis, cholecystitis)

Acute pancreatitis, reported infrequently

Hypersensitivity and injection-site reactions recorded under the study protocols

Thyroid C-cell tumours observed in rodent studies — the basis of the reference medicine’s boxed warning; human relevance reported as unconfirmed

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

A transient resting-heart-rate increase of a few bpm was recorded as a measured endpoint

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Tirzepatide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Tier 1 · Human clinical

SURMOUNT-1 obesity RCT — −20.9% mean change from baseline in body weight at week 72 (NEJM 2022; PMID 35658024)

SURMOUNT-5 head-to-head RCT vs semaglutide — −20.2% vs −13.7% at week 72 (NEJM 2025; PMID 40353578)

SURPASS-CVOT cardiovascular-outcomes RCT — 13,000+ participants (NEJM 2025); SURPASS diabetes programme

Certificates, databases & peer-reviewed sources

Last reviewed: 14 August 2026 · New-U Research Compounds

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. · 2022 · PMID: 35658024 · DOI: 10.1056/NEJMoa2206038

Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. · 2025 · PMID: 40353578 · DOI: 10.1056/NEJMoa2416394

SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. · 2025 · DOI: 10.1056/NEJMoa2505928

PubMed: peer-reviewed literature on Tirzepatide

ClinicalTrials.gov: registered studies on Tirzepatide

Tirzepatide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

39-amino-acid synthetic peptide built on the GIP backbone (LY3298176)

Dual GIPR / GLP-1R agonist activity characterised with imbalanced agonism

Aib2 and Aib13 substitutions investigated for DPP-IV and protease resistance

C20 fatty-diacid modification reported to give 99% albumin binding

Apparent elimination half-life reported at approximately 5 days in published pharmacokinetic research

GLP1-RC-TZ laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not the finished pharmaceutical studied in the cited trials

Specifications

New-U catalogue identifier GLP1-RC-TZ Scientific subject Tirzepatide (LY3298176) Molecular Weight 4,813.53 Da Receptors characterised GIPR (full agonist), GLP-1R (cAMP-biased) Purity (analytical) >99% by RP-HPLC area normalisation Identity (analytical) Confirmed by mass spectrometry on the released batch Form Lyophilised powder Published half-life Approximately 5 days, mean 116.7 h (external pharmacokinetic research) Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light. Intended use Laboratory research material. Not for human or veterinary use.

Tirzepatide Research — GLP1-RC-TZ Laboratory Research Material

Tirzepatide is the most extensively characterised dual-incretin ("twincretin") peptide in the published literature. Receptor-pharmacology studies describe full GIPR agonist potency layered onto a cAMP-biased GLP-1R signal, and the clinical programme includes one trial, SURMOUNT-5 (NEJM 2025), specifically designed as a head-to-head comparison against semaglutide.

Published clinical research of the reference medicine reports protocol-defined endpoints: a mean change from baseline in body weight of −20.9% at week 72 in the SURMOUNT-1 15 mg arm (NEJM 2022), −20.2% vs −13.7% against semaglutide at week 72 in SURMOUNT-5 (NEJM 2025), an ~8% relative reduction in major adverse cardiovascular events against dulaglutide in SURPASS-CVOT (NEJM 2025), and HbA1c reductions of up to 2.58% in the SURPASS programme. Each of those figures belongs to the study, population and timepoint that produced it.

New-U Research Compounds supplies GLP1-RC-TZ as lyophilised, analytically verified laboratory research material at >99% HPLC purity, with identity and purity confirmed by independent laboratories. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material. GLP1-RC-TZ is not an approved medicine, is not the finished pharmaceutical studied in the cited trials, and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

Gastric inhibitory polypeptide - Wikipedia

More in Metabolic Research

Tirzepatide vs related Metabolic Research compounds

Compound Price Purity spec COA Tirzepatide from $160 >99% HPLC 2 published batches Retatrutide from $200 >99% HPLC 4 published batches Semaglutide from $150 >99% HPLC 1 published batch

Tirzepatide vs Retatrutide - full comparison

Tirzepatide vs Semaglutide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Tirzepatide

Tirzepatide research guide

Buy Tirzepatide - pricing & packs

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.